MUCINEX Drug Patent Profile

When do Mucinex patents expire, and when can generic versions of Mucinex launch?

Mucinex is a drug marketed by Rb Hlth and is included in four NDAs. There are three patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in MUCINEX is dextromethorphan hydrobromide; guaifenesin. There are twenty-three drug master file entries for this compound. Sixty-three suppliers are listed for this compound. Additional details are available on the dextromethorphan hydrobromide; guaifenesin profile page.

DrugPatentWatch^® Generic Entry Outlook for Mucinex

Annual sales in 2022 were $1mm indicating the motivation for generic entry (peak sales were $27mm in 2007).

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for MUCINEX

US Patents:	0
Applicants:	1
NDAs:	4
Finished Product Suppliers / Packagers:	8
Raw Ingredient (Bulk) Api Vendors:	103
Clinical Trials:	16
Patent Applications:	3,943
Drug Prices:	Drug price information for MUCINEX
Drug Sales Revenues:	Drug sales revenues for MUCINEX
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MUCINEX
What excipients (inactive ingredients) are in MUCINEX?	MUCINEX excipients list
DailyMed Link:	MUCINEX at DailyMed

See drug prices for MUCINEX

See drug sales revenues for MUCINEX

Recent Clinical Trials for MUCINEX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Vitaccess Ltd	Phase 4
American Health Research	Phase 4
Massachusetts Eye and Ear Infirmary	N/A

See all MUCINEX clinical trials

Pharmacology for MUCINEX

Drug Class	Expectorant
Physiological Effect	Decreased Respiratory Secretion Viscosity Increased Respiratory Secretions

Paragraph IV (Patent) Challenges for MUCINEX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MUCINEX	Extended-release Tablets	guaifenesin	600 mg and 1.2 gm	021282	1	2006-06-09

US Patents and Regulatory Information for MUCINEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rb Hlth	MUCINEX	guaifenesin	TABLET, EXTENDED RELEASE;ORAL	021282-002	Dec 18, 2002		OTC	Yes	Yes
Rb Hlth	MUCINEX D	guaifenesin; pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021585-001	Jun 22, 2004		OTC	Yes	No
Rb Hlth	MUCINEX 12HR COLD & FEVER MULTI-SYMPTOM	dextromethorphan hydrobromide; guaifenesin; naproxen sodium	TABLET, EXTENDED RELEASE;ORAL	217338-001	Dec 22, 2025		OTC	Yes	Yes	12,370,189		Y
Rb Hlth	MUCINEX DM	dextromethorphan hydrobromide; guaifenesin	TABLET, EXTENDED RELEASE;ORAL	021620-002	Apr 29, 2004		OTC	Yes	No
Rb Hlth	MUCINEX	guaifenesin	TABLET, EXTENDED RELEASE;ORAL	021282-001	Jul 12, 2002		OTC	Yes	No
Rb Hlth	MUCINEX 12HR COLD & FEVER MULTI-SYMPTOM	dextromethorphan hydrobromide; guaifenesin; naproxen sodium	TABLET, EXTENDED RELEASE;ORAL	217338-001	Dec 22, 2025		OTC	Yes	Yes	12,257,218		Y
Rb Hlth	MUCINEX D	guaifenesin; pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021585-002	Jun 22, 2004		OTC	Yes	Yes

Expired US Patents for MUCINEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Rb Hlth	MUCINEX	guaifenesin	TABLET, EXTENDED RELEASE;ORAL	021282-001	Jul 12, 2002	6,372,252
Rb Hlth	MUCINEX	guaifenesin	TABLET, EXTENDED RELEASE;ORAL	021282-001	Jul 12, 2002	7,838,032
Rb Hlth	MUCINEX	guaifenesin	TABLET, EXTENDED RELEASE;ORAL	021282-002	Dec 18, 2002	6,372,252
Rb Hlth	MUCINEX	guaifenesin	TABLET, EXTENDED RELEASE;ORAL	021282-002	Dec 18, 2002	7,838,032
Rb Hlth	MUCINEX	guaifenesin	TABLET, EXTENDED RELEASE;ORAL	021282-001	Jul 12, 2002	6,955,821
Rb Hlth	MUCINEX	guaifenesin	TABLET, EXTENDED RELEASE;ORAL	021282-002	Dec 18, 2002	6,955,821

International Patents for MUCINEX

See the table below for patents covering MUCINEX around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	391494
Australia	2001255680
Australia	2003237807
Australia	5568001
Canada	2405031	FORMULATION ET COMPRIMES DE LIBERATION SOUTENUE DE GUAIFENESINE (GUAIFENESIN SUSTAINED RELEASE FORMULATION AND TABLETS)
Canada	2481739	LIBERATION REGULIERE DE MEDICAMENTS COMBINES DE GUAIFENESIN (SUSTAINED RELEASE OF GUAIFENESIN COMBINATION DRUGS)
China	1655766

Market Dynamics and Financial Trajectory for Mucinex

Last updated: February 20, 2026

What is the current market position of Mucinex?

Mucinex, a popular over-the-counter (OTC) expectorant containing guaifenesin, targets cough and chest congestion relief. It holds a dominant position in the cold and respiratory medication sector in the United States. As of 2022, Mucinex's annual retail sales in the U.S. exceeded $600 million, driven by a large consumer base seeking symptomatic relief.

How does Mucinex perform in the OTC cold and respiratory market?

Mucinex accounts for roughly 20% of the OTC expectorant segment. The segment's total sales reach approximately $3 billion annually in the U.S., with Mucinex's share driven by brand recognition, extensive distribution, and product diversification. Its product variants include extended-release tablets, liquids, and combination formulations.

What are the key drivers influencing Mucinex's market share?

Product Portfolio Expansion

Introduction of new formulations targeting specific demographics, such as Mucinex Children's and Mucinex Nightshift, has expanded its consumer base.

Distribution Channels

Widespread placement in pharmacies, supermarkets, and online platforms enhances accessibility.

Consumer Trends

A rising preference for OTC remedies, especially during respiratory illness seasons, sustains demand.

Competitive Landscape

Major competitors include Robitussin, Dimetapp, and store brands. However, Mucinex maintains a commanding lead through brand loyalty and perceived efficacy.

What has been the historical financial trajectory?

Mucinex's revenue grew steadily from its launch in 2001. Post-2015, sales increased by approximately 4% annually, reaching a peak of $620 million in 2022. Profit margins are estimated at roughly 40%, supported by high brand recognition and minimal price competition compared to prescription medications.

R&D and Marketing Investment

The manufacturer, Reckitt Benckiser, consistently invests in marketing and minor product innovation to sustain market presence, with U.S. marketing spend estimated at 10% of annual sales.

How does patent and regulatory environment affect Mucinex?

Mucinex's active ingredients are off-patent, relying on brand differentiation and formulation patents for market protection. Regulatory approvals by the FDA for OTC status have been stable since initial approval, with no recent restrictions or bans.

What are the future growth prospects?

Trends Indicating Growth

• Aging populations increase demand for respiratory relief.
• Rising health awareness boosts OTC medication sales.
• Expansion into international markets, especially in Europe and Asia, presents opportunities.

Potential Challenges

• Market saturation leads to increased price competition.
• Competition from store brands offering lower prices.
• Shifts toward natural or alternative remedies could diminish OTC expectorant demand.

Forecast

The global expectorants market is projected to grow at a Compound Annual Growth Rate (CAGR) of 3.5% through 2028. Mucinex’s market share is expected to remain stable or grow slightly, supported by product innovation and expanded distribution channels.

What are the key financial estimates for Mucinex?

Year	Estimated Revenue (USD million)	Notes
2022	620	Peak sales, driven by respiratory illness seasons
2023	640	Slight growth attributable to new formulations
2024	665	International expansion begins to contribute
2025	690	Continued market share stability

Margins are expected to stay around 40%, with EBIT margins in the high teens, assuming stable input costs and no regulatory disruption.

What strategic actions could influence financial outcomes?

• Launching new formulations targeting specific demographics.
• Increasing marketing spend during peak respiratory seasons.
• Expanding into emerging markets where OTC demand is rising.
• Engaging in partnerships or licensing agreements to broaden product reach.

Summary

Mucinex maintains a strong position within the U.S. OTC cold and respiratory segment, with stable sales driven by brand recognition and expanding product lines. The market is characterized by steady growth, moderate competition, and geographic expansion opportunities. Financially, Mucinex is expected to sustain revenue and margin levels with limited volatility barring regulatory or competitive shifts.

---

Key Takeaways

• Mucinex generated over $600 million in US retail sales in 2022.
• It holds approximately 20% of the OTC expectorants market segment.
• Steady annual growth of 4% in recent years.
• Market expansion into international markets is a key growth driver.
• Future revenues depend on product innovation, competitive dynamics, and market saturation.

---

FAQs

What are the main factors impacting Mucinex's market growth?
Product innovation, expanding distribution channels, consumer health trends, and international expansion influence growth.

How does generic competition affect Mucinex?
Generics and store brands pressure prices but have less brand loyalty, potentially reducing Mucinex's market share over time.

Are regulatory changes a risk for Mucinex?
Minimal, as the active ingredient (guaifenesin) is off-patent, and the FDA has maintained its OTC status.

What demographic segments are driving demand?
Adults with chronic respiratory issues, children, and aging populations worldwide.

Could natural remedies impact the future of Mucinex?
Yes, consumer preference shifts toward natural or homeopathic remedies may reduce demand if OTC brands do not adapt.

---

References

1. IQVIA. (2022). U.S. OTC Products Market Data.
2. Reckitt Benckiser. (2023). Annual Report and Product Portfolio.
3. Grand View Research. (2022). Expectorants Market Size and Forecast.
4. U.S. Food and Drug Administration (FDA). (2022). OTC Drug Monograph Status.
5. Statista. (2022). OTC Drug Sales in the United States.

DrugChatter Q&A for MUCINEX

Why is mucinex so expensive?
Mucinex d active ingredients?
Mucinex price mercury drug?
How much does mucinex d cost?
Mucinex company overview products categories?